CHIEF-HF: Improvement in Heart Failure Symptoms at 12 Wk With Canagliflozin vs Placebo

November 13-15, 2021; Virtual
In this virtually conducted clinical trial, no physician visits occurred and data were collected via smart phone app.
Format: Microsoft PowerPoint (.ppt)
File Size: 214 KB
Released: December 3, 2021

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Merck

Related Content

Dr Milda Saunders discusses strategies to erase health disparities in the most vulnerable patients with anemia of CKD, from Clinical Care Options (CCO)

Milda Saunders, MD, MPH Released: December 2, 2022

Expert commentary on management and challenges when treating patients with anemia of CKD, from Clinical Care Options (CCO)

person default Ajay Singh, MBBS, FRCP, MBA Released: November 28, 2022

Unlocked downloadable slides featuring experts insight on the management of patients with obesity from Clinical Care Options (CCO).

Caroline Apovian, MD Ken Fujioka, MD Released: November 2, 2022

Concise microlearning module featuring expert insight on the cardiorenal benefits of SGLT2 inhibitors in T2D from Clinical Care Options (CCO)

Jennifer B. Green, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Released: July 12, 2022 Expired: July 11, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings